K Number
K234055
Device Name
DEKA Loop
Date Cleared
2024-03-13

(82 days)

Product Code
Regulation Number
862.1356
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
DEKA Loop is intended for use with compatible integrated continuous glucose monitors (iCGM) and the DEKA alternate controller enabled (ACE) insulin infusion pump to automatically increase, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user's confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds. DEKA Loop is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater. DEKA Loop is intended for single patient use and requires a prescription.
Device Description
DEKA Loop is an interoperable Alternate Glycemic Controller (iAGC) and works to control an ACE (Alternate Controller Enabled) insulin pump to automatically increase, decrease, and suspend delivery of basal insulin based on readings from an iCGM (integrated continuous glucose monitor) and glucose values predicted by DEKA Loop. DEKA Loop can also recommend, and with the user's confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds. It is controlled by an iOS app that is downloaded to a user's iPhone.
More Information

Not Found

Yes
The device description explicitly mentions "glucose values predicted by DEKA Loop," which strongly suggests the use of predictive algorithms, a common application of machine learning in medical devices.

Yes
The device is intended for the management of Type 1 diabetes and automatically controls insulin delivery based on glucose readings, which are actions aimed at treating a medical condition.

No

Explanation: The device is designed to automatically increase, decrease, and suspend delivery of basal insulin, and recommend/control correction boluses based on iCGM readings and predicted glucose values. Its primary function is to manage glucose levels in individuals with Type 1 diabetes, not to diagnose the condition.

Yes

The device description explicitly states that DEKA Loop is an interoperable Alternate Glycemic Controller (iAGC) and is controlled by an iOS app downloaded to an iPhone. While it interacts with hardware (iCGM and insulin pump), the device itself, as described, is the software that performs the control and prediction functions. The summary focuses on software verification and validation and in-silico testing, further supporting its nature as a software-only device.

Based on the provided text, the DEKA Loop device is not an In Vitro Diagnostic (IVD).

Here's why:

  • IVDs are used to examine specimens from the human body. The DEKA Loop's intended use and description clearly state it works with an iCGM (which measures glucose in interstitial fluid, a bodily fluid) and an insulin pump to manage diabetes. While it uses data from a bodily fluid, its primary function is to control insulin delivery based on that data and predictions, not to diagnose or monitor a condition by analyzing a specimen in vitro (outside the body).
  • The description focuses on controlling an insulin pump. The core function is to automate and recommend insulin delivery, which is a therapeutic action, not a diagnostic one.
  • There is no mention of analyzing a specimen in a lab setting. The device operates in conjunction with an iCGM and an insulin pump in a home environment.

Therefore, the DEKA Loop falls under the category of a medical device that uses data from an IVD (the iCGM) to manage a condition, but it is not an IVD itself.

No
The input clearly states "Control Plan Authorized (PCCP) and relevant text Not Found," indicating the letter does not mention an approved or cleared PCCP.

Intended Use / Indications for Use

DEKA Loop is intended for use with compatible integrated continuous glucose monitors (iCGM) and the DEKA alternate controller enabled (ACE) insulin infusion pump to automatically increase, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user's confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds.

DEKA Loop is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.

DEKA Loop is intended for single patient use and requires a prescription.

Product codes

QJI

Device Description

DEKA Loop is an interoperable Alternate Glycemic Controller (iAGC) and works to control an ACE (Alternate Controller Enabled) insulin pump to automatically increase, decrease, and suspend delivery of basal insulin based on readings from an iCGM (integrated continuous glucose monitor) and glucose values predicted by DEKA Loop. DEKA Loop can also recommend, and with the user's confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds. It is controlled by an iOS app that is downloaded to a user's iPhone.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

six years of age and greater.

Intended User / Care Setting

Home environments; Single user only; Requires a prescription so likely used under the guidance of a healthcare professional.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Software verification and validation testing was performed per FDA's guidance document, Guidance for Industry and FDA Staff - Total Product Life Cycle: Infusion Pump - Premarket Notification 510(k) Submissions Guidance. Additionally, in-silico software challenge testing demonstrated clinical equivalence to the predicate device.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K203689

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 862.1356 Interoperable automated glycemic controller.

(a)
Identification. An interoperable automated glycemic controller is a device intended to automatically calculate drug doses based on inputs such as glucose and other relevant physiological parameters, and to command the delivery of such drug doses from a connected infusion pump. Interoperable automated glycemic controllers are designed to reliably and securely communicate with digitally connected devices to allow drug delivery commands to be sent, received, executed, and confirmed. Interoperable automated glycemic controllers are intended to be used in conjunction with digitally connected devices for the purpose of maintaining glycemic control.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) An appropriate, as determined by FDA, clinical implementation strategy, including data demonstrating appropriate, as determined by FDA, clinical performance of the device for its intended use, including all of its indications for use.
(A) The clinical data must be representative of the performance of the device in the intended use population and in clinically relevant use scenarios and sufficient to demonstrate appropriate, as determined by FDA, clinical performance of the device for its intended use, including all of its indications for use.
(B) For devices indicated for use with multiple therapeutic agents for the same therapeutic effect (
e.g., more than one type of insulin), data demonstrating performance with each product or, alternatively, an appropriate, as determined by FDA, clinical justification for why such data are not needed.(C) When determined to be necessary by FDA, the strategy must include postmarket data collection to confirm safe real-world use and monitor for rare adverse events.
(ii) Results obtained through a human factors study that demonstrates that an intended user can safely use the device for its intended use.
(iii) A detailed and appropriate, as determined by FDA, strategy to ensure secure and reliable means of data transmission with other intended connected devices.
(iv) Specifications that are appropriate, as determined by FDA, for connected devices that shall be eligible to provide input to (
e.g., specification of glucose sensor performance) or accept commands from (e.g., specifications for drug infusion pump performance) the controller, and a detailed strategy for ensuring that connected devices meet these specifications.(v) Specifications for devices responsible for hosting the controller, and a detailed and appropriate, as determined by FDA, strategy for ensuring that the specifications are met by the hosting devices.
(vi) Documentation demonstrating that appropriate, as determined by FDA, measures are in place (
e.g., validated device design features) to ensure that safe therapy is maintained when communication with digitally connected devices is interrupted, lost, or re-established after an interruption. Validation testing results must demonstrate that critical events that occur during a loss of communications (e.g., commands, device malfunctions, occlusions, etc.) are handled and logged appropriately during and after the interruption to maintain patient safety.(vii) A detailed plan and procedure for assigning postmarket responsibilities including adverse event reporting, complaint handling, and investigations with the manufacturers of devices that are digitally connected to the controller.
(2) Design verification and validation documentation must include appropriate design inputs and design outputs that are essential for the proper functioning of the device that have been documented and include the following:
(i) Risk control measures to address device system hazards;
(ii) Design decisions related to how the risk control measures impact essential performance; and
(iii) A traceability analysis demonstrating that all hazards are adequately controlled and that all controls have been validated in the final device design.
(3) The device shall include appropriate, as determined by FDA, and validated interface specifications for digitally connected devices. These interface specifications shall, at a minimum, provide for the following:
(i) Secure authentication (pairing) to connected devices;
(ii) Secure, accurate, and reliable means of data transmission between the controller and connected devices;
(iii) Sharing of necessary state information between the controller and any connected devices (
e.g., battery level, reservoir level, sensor use life, pump status, error conditions);(iv) Ensuring that the controller continues to operate safely when data is received in a manner outside the bounds of the parameters specified;
(v) A detailed process and procedures for sharing the controller's interface specification with connected devices and for validating the correct implementation of that protocol; and
(vi) A mechanism for updating the controller software, including any software that is required for operation of the controller in a manner that ensures its safety and performance.
(4) The device design must ensure that a record of critical events is stored and accessible for an adequate period to allow for auditing of communications between digitally connected devices, and to facilitate the sharing of pertinent information with the responsible parties for those connected devices. Critical events to be stored by the controller must, at a minimum, include:
(i) Commands issued by the controller, and associated confirmations the controller receives from digitally connected devices;
(ii) Malfunctions of the controller and malfunctions reported to the controller by digitally connected devices (
e.g., infusion pump occlusion, glucose sensor shut down);(iii) Alarms and alerts and associated acknowledgements from the controller as well as those reported to the controller by digitally connected devices; and
(iv) Connectivity events (
e.g., establishment or loss of communications).(5) The device must only receive glucose input from devices cleared under § 862.1355 (integrated continuous glucose monitoring system), unless FDA determines an alternate type of glucose input device is designed appropriately to allow the controller to meet the special controls contained within this section.
(6) The device must only command drug delivery from devices cleared under § 880.5730 of this chapter (alternate controller enabled infusion pump), unless FDA determines an alternate type of drug infusion pump device is designed appropriately to allow the controller to meet the special controls contained within this section.
(7) An appropriate, as determined by FDA, training plan must be established for users and healthcare providers to assure the safety and performance of the device when used. This may include, but not be limited to, training on device contraindications, situations in which the device should not be used, notable differences in device functionality or features compared to similar alternative therapies, and information to help prescribers identify suitable candidate patients, as applicable.
(8) The labeling required under § 809.10(b) of this chapter must include:
(i) A contraindication for use in pediatric populations except to the extent clinical performance data or other available information demonstrates that it can be safely used in pediatric populations in whole or in part.
(ii) A prominent statement identifying any populations for which use of this device has been determined to be unsafe.
(iii) A prominent statement identifying by name the therapeutic agents that are compatible with the controller, including their identity and concentration, as appropriate.
(iv) The identity of those digitally connected devices with which the controller can be used, including descriptions of the specific system configurations that can be used, per the detailed strategy submitted under paragraph (b)(1)(iii) of this section.
(v) A comprehensive description of representative clinical performance in the hands of the intended user, including information specific to use in the pediatric use population, as appropriate.
(vi) A comprehensive description of safety of the device, including, for example, the incidence of severe hypoglycemia, diabetic ketoacidosis, and other relevant adverse events observed in a study conducted to satisfy paragraph (b)(1)(i) of this section.
(vii) For wireless connection enabled devices, a description of the wireless quality of service required for proper use of the device.
(viii) For any controller with hardware components intended for multiple patient reuse, instructions for safely reprocessing the hardware components between uses.

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

March 13, 2024

Deka Research and Development Paul Smolenski Regulatory Affairs 340 Commercial Street Manchester, New Hampshire 03101

Re: K234055

Trade/Device Name: DEKA Loop Regulation Number: 21 CFR 862.1356 Regulation Name: Interoperable Automated Glycemic Controller Regulatory Class: Class II Product Code: QJI Dated: December 21, 2023 Received: December 22, 2023

Dear Paul Smolenski:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

1

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Joshua Balsam -S

Joshua M. Balsam, Ph.D. Branch Chief Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health

2

Indications for Use

510(k) Number (if known) K234055

Device Name DEKA Loop

Indications for Use (Describe)

DEKA Loop is intended for use with compatible integrated continuous glucose monitors (iCGM) and the DEKA alternate controller enabled (ACE) insulin infusion pump to automatically increase, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user's confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds.

DEKA Loop is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.

DEKA Loop is intended for single patient use and requires a prescription.

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

510(k) Summary: K234055

Submitter Information

510(k) Sponsor: DEKA Research & Development 340 Commercial Street Manchester, NH 03101

Contact Person: Paul Smolenski Regulatory Affairs DEKA Research & Development Corporation Phone: (603) 669-5139 Fax: (603) 624-0573 psmolenski(@dekaresearch.com

Date Prepared: 2/29/2024

Proposed Device

Common/Usual Name: DEKA Loop Trade/Proprietary Name: DEKA Loop Classification Name: interoperable Automated Glycemic Controller Device Classification: 21 CFR 862.1356 Product Code: QJI Class: II Device Panel: Clinical Chemistry

Predicate Device

The predicate device for this submission is Tidepool Loop cleared in K203689.

Device Description

DEKA Loop is an interoperable Alternate Glycemic Controller (iAGC) and works to control an ACE (Alternate Controller Enabled) insulin pump to automatically increase, decrease, and suspend delivery of basal insulin based on readings from an iCGM (integrated continuous glucose monitor) and glucose values predicted by DEKA Loop. DEKA Loop can also recommend, and with the user's confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds. It is controlled by an iOS app that is downloaded to a user's iPhone.

Intended Use

DEKA Loop is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend and deliver correction boluses when glucose values are predicted to exceed user configurable thresholds. DEKA Loop is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater. DEKA Loop is intended for single patient use and requires a prescription.

4

Technological Characteristics

DEKA Loop is used with an ACE pump and an iCGM to deliver basal insulin.

Performance Data

Software verification and validation testing was performed per FDA's guidance document, Guidance for Industry and FDA Staff - Total Product Life Cycle: Infusion Pump - Premarket Notification 510(k) Submissions Guidance. Additionally, in-silico software challenge testing demonstrated clinical equivalence to the predicate device.

5

Substantial Equivalence

DEKA Loop is substantially equivalent to the predicate device, Tidepool Loop, as cleared in K203689. The table belows a comparison of the technological, functional, and performance characteristics between the subject and predicate devices.

CharacteristicPredicate DeviceSubject DeviceExplanation of Differences
Device ClassificationInteroperable Automated GlycemicInteroperable Automated GlycemicSame
Regulation andController, 21 CFR 862.1356,Controller, 21 CFR 862.1356,
Product CodeProcode QJIProcode QJI
Indications for UseTidepool Loop, a mobile application
with algorithm technology, is
intended for use with compatible
integrated continuous glucose
monitors (iCGM) and alternate
controller enabled (ACE) insulin
infusion pumps to automatically
increase, decrease, and suspend
delivery of basal insulin based on
iCGM readings and predicted
glucose values. It can also
recommend, and with the user's
confirmation, control the delivery of
correction boluses when glucose
values are predicted to exceed user
configurable thresholds.

Tidepool Loop is intended for the
management of type 1 diabetes
mellitus in persons six years of age
and greater.

Tidepool Loop is intended for single
patient use. | DEKA Loop is intended for use
with compatible integrated
continuous glucose monitors
(iCGM) and the DEKA alternate
controller enabled (ACE) insulin
infusion pump to automatically
increase, decrease, and suspend
delivery of basal insulin based on
iCGM readings and predicted
glucose values. It can also
recommend, and with the user's
confirmation, control the delivery of
correction boluses when glucose
values are predicted to exceed user
configurable thresholds.

DEKA Loop is intended for the
management of Type 1 diabetes
mellitus in persons six years of age
and greater.

DEKA Loop is intended for single
patient use and requires a
prescription. | Equivalent. DEKA Loop is
integrated into the DEKA
ACE Pump System. |
| Characteristic | Predicate Device | Subject Device | Explanation of Differences |
| Prescription Use | Tidepool Loop is Rx - For
Prescription Use Only. | Yes | Same |
| Intended Population | Yes
Type 1 diabetes mellitus in persons
six years of age and greater. | Type 1 diabetes mellitus in persons
six years of age and greater. | Same |
| Patient Environment | On-body wearable ambulatory
pump | On-body wearable ambulatory
pump | Same |
| Environment of Use | Home environments | Home environments | Same |
| Number of Users | Single user only | Single user only | Same |
| Technological Characteristics | | | |
| Principle of Operation | Tidepool Loop predicts glucose
levels up to 6 hours in the future
(the approximate duration of insulin
action for U-100 rapid-acting
insulin) based on prior iCGM
readings, insulin delivery history,
and user input (e.g., carbohydrate
intake and exercise) and uses that
prediction to adjust insulin delivery.

Tidepool Loop can be used to adjust
or suspend basal insulin delivery
every 5 minutes and deliver
correction boluses of insulin based
on actual and predicted CGM sensor
readings.

Users must manually deliver meal
boluses they can calculate using the
Tidepool Loop Bolus
Recommendation Tool | DEKA Loop predicts glucose levels
up to 6 hours in the future (the
approximate duration of insulin
action for U-100 rapid-acting
insulin) based on prior iCGM
readings, insulin delivery history,
and user input (e.g., carbohydrate
intake and exercise) and uses that
prediction to adjust insulin delivery.

DEKA Loop can be used to adjust
or suspend basal insulin delivery
every 5 minutes and deliver
correction boluses of insulin based
on actual and predicted CGM sensor
readings.

Users must manually deliver meal
boluses they can calculate using the
DEKA Loop Bolus
Recommendation Tool | Same |
| Characteristic | Predicate Device | Subject Device | Explanation of Differences |
| | (TLBRT) and can manually adjust
insulin delivery (change basal rates
and deliver insulin boluses) when
Tidepool Loop is active. | (DLBRT) and can manually adjust
insulin delivery (change basal rates
and deliver insulin boluses) when
DEKA Loop is active. | |
| Type of Algorithm | Hybrid Closed Loop – predictive
control | Hybrid Closed Loop – predictive
control | Same |
| Compatible iCGM | Dexcom G6 | Dexcom G6 | Same |
| Compatible ACE
Pump | An ACE pump that has the
specifications and meets the pre-
specified acceptance criteria for
software, cybersecurity, device
interoperability, human factors,
labeling, and training materials as
described in SOP-0016, "Tidepool
Loop Connected Device Integration
and Validation Process and Plan,"
and SOP-0018, "Tidepool Loop
Regulatory Determination Process."
Tidepool Loop must not be
distributed until the pre-specified
acceptance criteria in the SOPs are
met. | DEKA ACE Pump System | Equivalent. Both require
cleared ACE Pumps. In the
DEKA ACE Pump System,
the integration aspects of the
predicate device are
addressed by embedding
DEKA Loop into the DEKA
ACE Pump System. |
| Device Design or
Material | Tidepool Loop is a mobile
application and a Software as
Medical Device (SaMD) installed
on a host mobile device. | DEKA Loop is embedded in the
DEKA ACE Pump. The user
interface for DEKA Loop is the
DEKA Loop App iOS application. | Equivalent. DEKA Loop is
embedded in the DEKA
ACE pump instead of a host
mobile device. The user
interface for both systems is
an iOS application. Both the
subject and predicate devices
have equivalent risks and
mitigations for each use |
| Characteristic | Predicate Device | Subject Device | Explanation of Differences |
| Algorithm Platform | iPhone | DEKA ACE Pump System | Equivalent. Both the subject
and predicate devices have
equivalent risks and
mitigations for each use
profile. No new or modified
risks. |
| Insulin Compatibility | Novolog or Humalog U-100 | Novolog or Humalog U-100 | Same |
| Functional Characteristics | | | |
| User-controlled Target
Range Settings | Customizable settings
Correction Range:
87 - 180 mg/dL

Pre-Meal Range:
Glucose Safety Limit (which can be
set from 67-110 mg/dL) - 130
mg/dL

Workout Range: the higher of 87
mg/dL or the Glucose Safety Limit
(which can be set from 67-110
mg/dL) - 250 mg/dL | Customizable settings
Correction Range:
87 - 180 mg/dL

Pre-Meal Range:
Glucose Safety Limit (which can be
set from 67-110 mg/dL) - 130
mg/dL

Workout Range: the higher of 87
mg/dL or the Glucose Safety Limit
(which can be set from 67-110
mg/dL) - 250 mg/dL | Same |
| Auto-populating bolus
recommendation
based on iCGM value:
• In closed loop
mode
• In open loop
mode | Yes
No | Yes
No | Same |
| Characteristic | Predicate Device | Subject Device | Explanation of Differences |
| Data List and Logging | Yes | Yes | Same |
| Daily Activity Records | Yes | Yes | Same |
| Average Data Display | Yes | Yes | Same |
| Changing Pump Settings | Yes | Yes | Same |
| Invite others to view data through authorization | Yes | Yes | Same |
| Password Required | Yes | Yes | Same |
| Performance Characteristics | | | |
| Bench Performance | Tidepool Loop performance was verified and validated through software verification testing. | DEKA Loop performance was verified and validated through software verification testing. | Same |
| Clinical Performance | Tidepool Loop clinical performance is supported by representative 1,250 participants in a 15 months duration real-world, observational, single arm study of DIY Loop including both pediatric and adult participants. | In silico testing. | Equivalent. In silico testing proves that the DEKA Loop algorithm is clinically equivalent to the Tidepool Loop Algorithm. |
| Risk Assessment | Tidepool Loop performed Risk Assessment including detailed hazard analysis based on ISO 14971. | DEKA Loop performed Risk Assessment including detailed hazard analysis based on ISO 14971. | Same |
| Labeling | | | |
| Training | Tidepool Loop includes mandatory in-app learning and setup (user training) before the user can use Tidepool Loop. | Training of features related to DEKA Loop is associated with the DEKA ACE Pump System. | Equivalent.
Training on features associated with the integration of DEKA Loop within the DEKA ACE |
| Characteristic | Predicate Device | Subject Device | Explanation of Differences |
| | | | Pump System and the impact
on safety and effectiveness
were evaluated through
Human Factors testing and
found to have no impact. |
| User Guide | Tidepool Loop electronic User
Guide also includes all special
controls, clinical performance
information and other information
needed per cybersecurity and
interoperability requirements. | Labeling related to DEKA Loop is
associated with the DEKA ACE
Pump System.
The DEKA ACE Pump System user
guide includes all special controls,
clinical performance information
and other information needed per
cybersecurity and interoperability
requirements. | Equivalent. |

6

7

8

9

10

11

Conclusion

DEKA Loop is substantially equivalent to the predicate Tidepool Loop cleared in K203689. The differences, summarized in this submission, do not raise different questions of safety or effectiveness. The performance of the device is supported by DEKA's design control process which included non-clinical testing and risk management activities. The device meets all Special Controls for this product type as required by 21 CFR 862.1356 for interoperable Automated Glycemic Controllers, Product Code QJI.